Status:
COMPLETED
A Study of Single and Repeated Doses of LY3556050 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to conduct blood tests to measure how much LY3556050 is in the bloodstream and to determine if any age, gender, or food effects exist. The study will also evaluate th...
Eligibility Criteria
Inclusion
- Are overtly healthy as determined by medical evaluation.
- Participants with a body mass index (BMI) of 18.0 to 35.0 kilograms per square meter (kg/m²) and have body weight of 50 kg or more.
Exclusion
- Has any history of or active cardiac disease, including congestive heart failure, angina, any arrhythmia, or clinically significant findings on Electrocardiogram (ECG).
- Has diabetes mellitus, acromegaly, clinically active thyroid disease, or other active endocrinopathy.
- Has asthma or other severe respiratory disease.
- Is pregnant, lactating, or planning a pregnancy.
- Has active alcohol or substance abuse or history of alcohol or substance abuse within the 6 months prior to randomization.
- Any abnormal laboratory finding or vital signs outside specified parameters.
Key Trial Info
Start Date :
September 14 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 2 2017
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT05341102
Start Date
September 14 2016
End Date
June 2 2017
Last Update
April 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medpace Clinical Pharmacology, LLC
Cincinnati, Ohio, United States, 45227